What do systematic reviews say?

Rotasiil vs placebo

Rotasiil showed no clear difference in severe cases of all‐cause diarrhoea compared with placebo (high certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.92 [0.84, 1.01]
  2 studies · 11008 participants
  High
• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.94 [0.88, 1.01]
  2 studies · 11008 participants
  High

Rotasiil vs placebo

Rotasiil showed no clear difference in all‐cause death compared with placebo (moderate certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 1.14 [0.82, 1.59]
  2 studies · 11586 participants
  Moderate

Rotasiil vs placebo

Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.98 [0.92, 1.04]
  3 studies · 11646 participants
  High

Rotasiil vs placebo

Rotasiil showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.98 [0.35, 2.74]
  2 studies · 11586 participants
  Low

Rotavac vs placebo

Rotavac probably leads to lower severe cases of rotavirus diarrhoea compared with placebo (moderate certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.43 [0.3, 0.6]
  1 study · 6799 participants
  Moderate
• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.46 [0.35, 0.6]
  1 study · 6541 participants
  Moderate

Rotavac vs placebo

Rotavac probably leads to lower severe cases of all‐cause diarrhoea compared with placebo (moderate certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.84 [0.71, 0.98]
  1 study · 6799 participants
  Moderate
• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rotavac vs placebo

It is very uncertain whether rotavac changes all‐cause death compared with placebo (very low certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.88 [0.5, 1.56]
  2 studies · 8155 participants
  Very low

Rotavac vs placebo

Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 0.93 [0.85, 1.02]
  3 studies · 8210 participants
  Moderate

Rotavac vs placebo

It is very uncertain whether rotavac changes serious adverse events: intussusception compared with placebo (very low certainty).

• Vaccines for preventing rotavirus diarrhoea: vaccines in use 2021 · Cochrane Headline outcomes only
  RR 1.33 [0.35, 5.02]
  4 studies · 8582 participants
  Very low

Intervention not reported

The intervention probably leads to lower clinical malaria (moderate certainty).

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  Rate ratio 0.78 [0.69, 0.88]
  8 studies · 8774 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in hospital admission for any reason (moderate certainty).

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  Rate ratio 0.98 [0.76, 1.27]
  1 study · 684 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in anaemia (moderate certainty).

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  Rate ratio 0.77 [0.53, 1.12]
  1 study · 684 participants
  Moderate

Intervention not reported

The intervention probably leads to lower clinical malaria (moderate certainty).

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  Rate ratio 0.42 [0.33, 0.54]
  1 study · 147 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in severe malaria (moderate certainty).

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  Rate ratio 1.29 [0.28, 5.98]
  1 study · 147 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in all‐cause mortality (low certainty).

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  Risk ratio 0.17 [0.01, 4.06]
  1 study · 147 participants
  Low

Intervention not reported

The intervention showed no clear difference in hospital admission for any reason (low certainty).

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  Rate ratio 1.58 [0.46, 5.42]
  1 study · 147 participants
  Low

Intervention not reported

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 147 participants
  Moderate

Intervention not reported

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 147 participants
  Moderate

Intervention not reported

The intervention leads to lower clinical malaria (high certainty).

• Intermittent preventive treatment for malaria in infants 2021 · Cochrane Headline outcomes only
  Rate ratio 0.78 [0.62, 0.97]
  1 study · 676 participants
  High